Page 93 - Read Online

Pippione et al. Steroidogenic enzymes in prostate cancer

Cancer Ther 2008;7:2348-57. Endocrinol 2016;422:182-91.
169. Tokai Pharmaceuticals Announces Clinical Update. Available from: 176. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders
http://www.businesswire.com/news/home/20160726005553/en/Tokai- GJ, Jenster G, Schroder FH, de Jong FH. Evidence of limited
Pharmaceuticals-Announces-Clinical-Update. [Last accessed on 13 contributions for intratumoral steroidogenesis in prostate cancer.
Nov 2017] Cancer Res 2010;70:1256-64.
170. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu 177. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic
J, Upadhyay SK, Auchus RJ, Sharifi N. Conversion of abiraterone enzymes and stem cell markers are upregulated during androgen
to D4A drives anti-tumour activity in prostate cancer. Nature deprivation in prostate cancer. Mol Med 2011;17:657-64.
2015;523:347-51. 178. Audet-Walsh E, Yee T, Tam IS, Giguere V. Inverse regulation of DHT
171. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska synthesis enzymes 5alpha-reductase types 1 and 2 by the androgen
K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, receptor in prostate cancer. Endocrinology 2017;158:1015-21.
Attard G. Interactions of abiraterone, eplerenone, and prednisolone 179. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene
with wild-type and mutant androgen receptor: a rationale for expression of steroid 5 alpha-reductase 2 in human prostate cancer:
increasing abiraterone exposure or combining with MDV3100. implications for finasteride therapy of prostate carcinoma. Prostate
2003;57:134-9.
Cancer Res 2012;72:2176-82. 180. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O’Brien
172. Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio SP, Rittmaster RS. Differential alterations in 5alpha-reductase type
M, Scagliotti GV. Understanding and overcoming the mechanisms of 1 and type 2 levels during development and progression of prostate
primary and acquired resistance to abiraterone and enzalutamide in cancer. Prostate 2005;63:231-9.
castration resistant prostate cancer. Cancer Treat Rev 2015;41:884-92. 181. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, Unge
173. Jernberg E, Thysell E, Bovinder YE, Rudolfsson S, Crnalic S, T, Andersson S, Rane A. Differential gene expression of steroid 5
Widmark A, Bergh A, Wikstrom P. Characterization of prostate cancer alpha-reductase 2 in core needle biopsies from malignant and benign
bone metastases according to expression levels of steroidogenic prostatic tissue. J Clin Endocrinol Metab 1997;82:2210-4.
enzymes and androgen receptor splice variants. PLoS One 182. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura
2013;8:e77407. Y, Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3)
174. Djusberg E, Jernberg E, Thysell E, Golovleva I, Lundberg P, Crnalic is overexpressed in hormone-refractory prostate cancer. Cancer Sci
S, Widmark A, Bergh A, Brattsand M, Wikström P. High levels of the 2008;99:81-6.
AR-V7 splice variant and co-amplification of the golgi protein coding 183. Feldman BJ, Feldman D. The development of androgen-independent
YIPF6 in AR amplified prostate cancer bone metastases. Prostate prostate cancer. Nat Rev Cancer 2001;1:34-45.
2017;77:625-38. 184. Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.
175. Hagberg Thulin M, Nilsson ME, Thulin P, Céraline J, Ohlsson C, Androgen receptor-dependent and -independent mechanisms driving
Damber J-E, Welén K. Osteoblasts promote castration-resistant prostate cancer progression: opportunities for therapeutic targeting
prostate cancer by altering intratumoral steroidogenesis. Mol Cell from multiple angles. Oncotarget 2017;8:3724-45.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017 361